Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study

Dow Jones

04/22

By Christopher Kuo

Inhibrx Biosciences provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer.

The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment.

The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells.

The company also said 42% of the trial's patients remained progression-free at the 6-month landmark.

The overall disease control rate was 87%, the company said.

The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma.

The FDA previously granted Fast Track designation to ozekibart in 2021.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

April 21, 2026 17:28 ET (21:28 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2629658640"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629658640\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629658640?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629658640","market":"nz","top_or_hot":-1,"title":"Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer. \n</p>\n<p>\n  The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment. \n</p>\n<p>\n  The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells. \n</p>\n<p>\n  The company also said 42% of the trial's patients remained progression-free at the 6-month landmark. \n</p>\n<p>\n  The overall disease control rate was 87%, the company said. \n</p>\n<p>\n  The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma. \n</p>\n<p>\n  The FDA previously granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation to ozekibart in 2021. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Biosciences Gives Updated Data From Cancer Treatment Study\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-22 05:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer. \n</p>\n<p>\n  The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment. \n</p>\n<p>\n  The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells. \n</p>\n<p>\n  The company also said 42% of the trial's patients remained progression-free at the 6-month landmark. \n</p>\n<p>\n  The overall disease control rate was 87%, the company said. \n</p>\n<p>\n  The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma. \n</p>\n<p>\n  The FDA previously granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation to ozekibart in 2021. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629658640","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629658640","pubTimestamp":1776806880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Inhibrx Biosciences provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer.The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment.The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells.The company also said 42% of the trial's patients remained progression-free at the 6-month landmark.The overall disease control rate was 87%, the company said.The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma.The F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INBX":"Inhibrx Biosciences","BK4139":"生物科技"},"translate_title":"Inhibrx Biosciences提供癌症治疗研究的最新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\nInhibrx Biosciences provided updated interim data from its Phase 1/2 study evaluating its treatment for colorectal cancer. \n\n\n  The biopharmaceutical company on Tuesday said its study showed an objective response rate of 20% per RECIST v1.1 criteria, meaning a fifth of the patients had a complete or partial response to the treatment. \n\n\n  The study evaluated the company's ozekibart treatment in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer. Ozekibart is an antibody treatment designed to kill cancer cells. \n\n\n  The company also said 42% of the trial's patients remained progression-free at the 6-month landmark. \n\n\n  The overall disease control rate was 87%, the company said. \n\n\n  The company plans to meet with the Food and Drug Administration in the second half of 2026 to discuss plans to start a first-line registrational trial. In April, the company plans to submit a Biologics License Applicataion to the FDA for ozekibart in conventional chondrosarcoma. \n\n\n  The FDA previously granted Fast Track designation to ozekibart in 2021. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2026 17:28 ET (21:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}